Speaker:

Chynna-Loren Sheremeta

Project Title:

Innovative Treatment for Paediatric Atopic Dermatitis.

Project Description:

Atopic dermatitis (AD) affects up to 20% of children globally, causing intense itching and skin lesions that significantly impact quality of life. Current treatments, including corticosteroids and monoclonal antibodies, have limitations such as adverse effects and needle phobia. Researchers at the University of Queensland are developing a novel approach using haematopoietic prostaglandin D2 synthase (HPGDS) inhibitors, which can be administered topically or orally. This method aims to reduce inflammation and promote healing without the drawbacks of existing therapies. Early studies in mouse models show promising results, suggesting that this new treatment could offer a safer, more effective solution for managing paediatric AD. Successful commercialization could revolutionize care for children suffering from this chronic condition.